 Spiolto® Respimat® (tiotropium/olodaterol) is Boehringer Ingelheim’s new advance in COPD maintenance therapy.

Spiolto® Respimat® provides significant improvements in lung function, breathlessness, quality of life and reduction of rescue medication use over Spiriva® Respimat®, right from the initial stages when patients need maintenance therapy.1

Spiolto® is administered via Respimat®, which actively** delivers a unique mist, meaning the patient just needs to take a slow deep breath.2-8

The clinical course of COPD and the TOviTO® clinical trial programme

In COPD, decreasing lung function causes breathlessness and leads to a downward spiral of reduced physical activity, worsening symptoms and further inactivity.9 Decreasing exercise capacity reduces quality of life and increases the risk of disability and death.10

The >15,000 patient TOviTO® Phase III clinical trial programme has been designed to evaluate the effect of Spiolto® Respimat® on many of these important elements in the clinical course of COPD.

Footnotes:
* Combined figures for HandiHaler® and Spiriva® Respimat® - the world’s most prescribed COPD maintenance treatment with over 40 million patient-years of real life experience across all COPD severities
** Respimat® delivers a metered dose of medication in a mist at the push of a button requiring just a slow deep breath from a patient.
Efficacy and safety results from TONADO® 1&2: the pivotal Phase III trials for Spiolto® Respimat®

Data from the pivotal Phase III TONADO® trials show Spiolto® Respimat® provides...

...consistent improvements in lung function over Spiriva® Respimat®

...significant improvements in quality of life over Spiriva® Respimat®

...significant improvements in breathlessness over Spiriva® Respimat®

...reduction in the use of rescue medication over Spiriva® Respimat®

...a comparable safety profile to tiotropium or olodaterol alone

Footnotes
* After 24 weeks
† Responder: a decrease in SGRQ total score at week 24 of ≥ 4.0 units from baseline
**The importance of immediate COPD management**

30% have severe/very severe disease (GOLD stage 3/4)  
50% have moderate COPD (GOLD stage 2)  
50% have moderate COPD (GOLD stage 2)

When the majority of patients first go to see their doctor, their disease has already progressed to stages when they need maintenance treatment.

Optimal management right from the start of maintenance therapy may give patients the best opportunity to manage their symptoms, stay active and avoid the downward spiral of COPD for as long as possible.

Further data from TONADO® 1&2

A post-hoc analysis shows that Spiolto® Respimat® more than doubles the improvement in lung function compared to Spiriva® Respimat® in patients who had no prior long-acting bronchodilator (LABD) at baseline.

Improvement in trough FEV1 after 24 weeks of treatment in patients with no prior long-acting bronchodilator treatment

For more media information on Boehringer Ingelheim’s respiratory portfolio visit: newscentre.boehringer-ingelheim.com